Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialSARS-CoV-2 감염 외래 환자에서 Casirivimab과 Imdevimab COVID-19 항체 조합의 바이러스학적 효능: 2상 용량 범위 무작위 임상 시험Clinical Trial Published on 2022-08-012022-09-12 Journal: JAMA Network Open [Category] SARS, 임상, 진단, [키워드] 95% CI Administered age Asymptomatic average baseline Casirivimab clinical collected COVID-19 death dose double-blind Efficacy efficacy analysis greater Hispanic Hospitalization hypersensitivity reactions Imdevimab in viral intravenous mean difference monoclonal antibody combination outcome Outpatient parallel-group participant Participants Patient patients Phase 2 Phase 3 Placebo placebo-controlled primary end point Randomized randomized clinical trial ranged Reactions reduced reduction reported risk factor SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event seronegative severe COVID-19 study drug Subcutaneous symptomatic symptomatic patient The United States Treatment Viral load were excluded white [DOI] 10.1001/jamanetworkopen.2022.25411 PMC 바로가기 [Article Type] Clinical Trial
A case of Bacillus subtilis var. natto bacteremia caused by ingestion of natto during COVID-19 treatment in a maintenance hemodialysis patient with multiple myelomaCase report Published on 2022-08-012022-10-05 Journal: Journal of infection and chemotherapy : official j [Category] 변종, 치료법, [키워드] acute respiratory syndrome Admission age association B. subtilis Bacillus subtilis Bacteremia Bacteria Bacterial Blood caused conditions coronavirus coronavirus disease COVID-19 Critical Culture cultures Diabetes Mellitus Diabetic diagnosed during treatment End-stage renal disease Hemodialysis hospital Immunocompromised immunosuppressive ingestion intestinal inflammation intestinal permeability malignant tumor Multiple myeloma nephropathy next-generation sequencer Patient risk steroid symptomatic the patient therapy Tocilizumab translocation treated Treatment vancomycin VAR [DOI] 10.1016/j.jiac.2022.05.006 [Article Type] Case report
Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: A prospective surveillance study천식 및 알레르기가 있는 자녀가 있는 가정에서 SARS-CoV-2 감염 및 전파 위험 요소: 전향적 감시 연구Article Published on 2022-08-012022-09-11 Journal: The Journal of Allergy and Clinical Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome adjusted hazard ratio adjusted odds ratio Adults allergic disease allergic diseases allergy analyses Asthma attack rate body mass body mass index calculated children conducted COVID-19 determine determined by eczema Factor food allergy household infection Household SARs household transmission Households identify incidence increased risk Infection infection risk modify nasal swab offer pandemic participant Participants people with asthma positive preventing infection Probability Regression analyses risk risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 variants secondary attack rate severe acute respiratory syndrome virus Surveillance symptomatic tested Transmission understanding upper respiratory Vaccine virus with infection [DOI] 10.1016/j.jaci.2022.05.014 PMC 바로가기 [Article Type] Article
Solid organ transplantation from donors with recent or current SARS-CoV-2 infection: A systematic review최근 또는 현재 SARS-CoV-2 감염이 있는 기증자의 고형 장기 이식: 체계적인 검토Review Published on 2022-08-012022-09-11 Journal: Anaesthesia, critical care & pain medicine [Category] COVID19(2023년), SARS, 치료기술, [키워드] anti-SARS-CoV-2 titer Cochrane COVID-19 Study Register complications COVID-19 COVID-19 symptoms cycle database died Donor donors dysfunction evaluate for inclusion heart Hospital stay IQR kidney kidneys liver lung median Mortality occurred organ Organ donation organ transplantation organs outcome Patient patients died positive recipient recipients rejection risk of transmission Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 viral Septic shock solid organ solid organ transplantation SOT Symptom symptomatic systematic review threshold Transmission Transplant two patients viral replication Viral transmission was performed Web of Science [DOI] 10.1016/j.accpm.2022.101098 PMC 바로가기 [Article Type] Review
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialClinical Trial Published on 2022-08-012022-10-05 Journal: The Lancet. Haematology [Category] Coronavirus, Fulltext, MERS, 임상, [키워드] 1:1 105 patient 105 patients adverse event adverse events all-cause mortality analysed Asian assigned Belgium benefit black bleeding event Brazil Clinical practice Complete country COVID-19 COVID-19 vaccine death died dose Efficacy and safety eligibility eligible participant enrolled enrolment evaluate event rate FIVE Follow-up had no hazard ratio hospitalisation hospitalised in both group increased risk India Inflammation intention-to-treat population International IQR main analysis men middle multicentre no difference non-critically ill patient one patient Open-label Outpatient participant Patient patients with COVID-19 Pneumonia primary efficacy endpoint Prophylactic Prophylaxis random randomisation randomised Randomly receive Registered risk factor Safety Safety Monitoring Board Sanofi severe disease severity Sex similar studies South Africa Spain Standard of care Standard-of-care symptom onset symptomatic thromboembolic complications Trial uterine bleeding was done weighed were assessed white with COVID-19 women [DOI] 10.1016/S2352-3026(22)00173-9 PMC 바로가기 [Article Type] Clinical Trial
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialClinical Trial Published on 2022-08-012022-10-05 Journal: The Lancet. Haematology [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 95% CI acute COVID-19 adjusted relative risk age Anti-inflammatory effects Antithrombotic antiviral properties assigned assumption Berlin body temperature clinically Control control group COVID-19 criteria death Efficacy eight eligible enoxaparin event rates foundation futility Germany heparin hospitalisation independent initial intention-to-treat population interim analysis investigator-initiated IQR Johanna major bleeding major bleeding event median age multicentre nine not reduce Older older patient Open-label outcome Outpatient parallel-group participant phase 3 trial Prevent Primary outcome Probability prothrombotic randomisation randomised Randomly receive Registered reported respiratory infection respiratory symptom risk Safety Monitoring Board Serious Adverse Event Standard of care statistical Study design study population Switzerland symptomatic Thromboprophylaxis Treatment Trial university University of Zurich was done were recorded with COVID-19 women [DOI] 10.1016/S2352-3026(22)00175-2 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trialArticle Published on 2022-08-012022-10-06 Journal: Lancet Reg Health Southeast Asia [Category] 진단, [키워드] 1:1 95% CI accelerate accelerated age Anti-viral treatment assessment baseline clearance clinical trial Comorbidities comparable Concentration COVID-19 COVID-19 illness defined demonstrated double-blind Endpoint evaluated funding greater greater transmissibility high risk individuals infected with SARS-CoV-2 Laboratory Limited median Mild multicentre mutate nasal Nasal spray nasal swab nitric oxide nostril parallel group Patient pharmaceutical Placebo placebo-controlled polymerase chain primary analysis population progression proportion provided Randomized randomized trial receiving reduce reverse transcription RT-PCR SARS-CoV-2 SARS-CoV-2 RNA secondary Seven study medication symptomatic the placebo group therapy Treatment treatment difference vaccination Viral load virus virus clearance virus RNA [DOI] 10.1016/j.lansea.2022.100036 PMC 바로가기 [Article Type] Article
COVID-19 in Children: Correlation Between Epidemiologic, Clinical Characteristics, and RT-qPCR Cycle Threshold ValuesObservational Study Published on 2022-08-012022-10-04 Journal: The Pediatric Infectious Disease Journal [Category] COVID19(2023년), SARS, 임상, [키워드] age Asymptomatic asymptomatic patient children children with COVID-19 clinical Clinical characteristics correlation COVID-19 COVID-19 cases COVID-19 diagnosis cross-sectional cycle determine Epidemiology Initially Level median Older Patient patients real-time qPCR Ricardo RT-qPCR SARS-COV-2 infection severity significantly lower Standard symptom onset symptomatic threshold value Viral load Viral RNA with COVID-19 [DOI] 10.1097/INF.0000000000003564 PMC 바로가기 [Article Type] Observational Study
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments알츠하이머병(NorAD)에서 연장 방출 구안파신을 사용한 노르아드레날린성 추가 요법: 무작위 임상 시험 및 COVID-19 수정안에 대한 연구 프로토콜Article Published on 2022-08-012022-09-11 Journal: Trials [Category] 임상, [키워드] activities activity Add-on therapy addition Adrenergic receptor affected Alzheimer's disease Alzheimer’s disease approved assessment Attention attention deficit baseline Brain burden cholinesterase inhibitor clinical trial Cognition cognitive Combination combination therapy COVID-19 Daily daily living determine disease disorder double-blind dysfunction evaluate Evidence executive Follow-up function Guanfacine Guanfacine. hyperactivity IMPROVE include interview inventory involved locus measure Mild mild to moderate moderate modulating Neuropsychiatric NorAD noradrenergic observation outcome participant pathological change pathological changes pathway Pathways Placebo placebo group placebo-controlled Primary outcome randomised receive receptor Regulation secondary Secondary outcomes Study protocol Symptom symptomatic synergistic synergistic effect Test the placebo group thought Treatment treatment group Trial [DOI] 10.1186/s13063-022-06190-3 PMC 바로가기 [Article Type] Article
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] antibodies benefit clinical conducted convalescent plasma Convalescent plasma therapy Course COVID-19 death determine died disease severity double blind duration of symptoms Effectiveness Endpoint enrolment Follow-up hazard ratio high-risk patient highest Hospital admission Hospitalized ICU admission IMPROVE in viral median age multicentre objective Odds ratio Older Outpatient outpatients Patient PCR primary endpoint randomization randomized placebo-controlled trial randomized trial recruitment Result risk factor RNA secondary severe COVID-19 Symptom symptom duration symptom onset symptomatic Symptoms the disease therapy for COVID-19 vaccination Viral RNA [DOI] 10.1016/j.cmi.2022.08.005 [Article Type] Research article